Discovery and structural optimization of novel 6-fluorobenzofuran-containing thiadiazole frameworks as potent methionine adenosyltransferase 2A (MAT2A) inhibitors

Authors: Azam, Uzma; Hasnat, Muhammad; Sarfraz, Hina; Hussain, Rafaqat; Naz, Sumaira; Ali, Syed Shujait; Binsaleh, Ammena Y; Al-Hoshani, Nawal; El Hadi Mohamed, Rania Ali

Source journal: Zeitschrift fur Naturforschung. C, Journal of biosciences (2026-11-20)

DOI: 10.1515/znc-2026-0188

Abstract

A library of novel benzofuran-thiadiazole derivatives 10-14 and 18-25 was synthesized, and their structures were unambiguously confirmed by spectroscopic techniques, including (1)H NMR, (13)C NMR, and HRMS. All synthesized compounds were evaluated for their in vitro MAT2A inhibitory activity, exhibiting IC(50) values ranging from 0.09584 to 12.87 muM, compared with the reference inhibitor AZ-28 (IC(50) = 0.0419 muM). Among the synthesized derivatives, compounds 23, 22, 14, 24, and 10 emerged as the most potent inhibitors, with IC(50) values of 0.09584, 0.3216, 0.4655, 1.560, and 1.595 muM, respectively. To elucidate the molecular basis underlying MAT2A inhibition and identify promising lead candidates, a comprehensive multistage computational investigation was performed, incorporating molecular docking, 100 ns molecular dynamics (MD) simulations, density functional theory (DFT), and ADMET profiling. Molecular docking analysis revealed that compound 23 exhibited the most favorable binding affinity within the MAT2A active site, with a docking score of -5.806 kcal/mol. The stability of the 23-MAT2A complex was subsequently assessed through 100 ns MD simulations, which supported the docking results and demonstrated a stable protein-ligand complex, characterized by an average RMSD of less than 2.6 A throughout the simulation. Furthermore, compound 23 displayed a favorable drug-likeness profile, including an encouraging predicted bioavailability score and overall pharmacokinetic and ADMET characteristics. Collectively, the experimental potency, favorable binding affinity, dynamic stability, and predicted pharmacokinetic properties establish compound 23 as the most promising lead candidate within the series. These findings provide a solid basis for the continued exploration and rational optimization of this scaffold toward the development of novel MAT2A inhibitors.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.